Work

A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx371.075

Authors: D. Bajorin, M.D. Galsky, J.E. Gschwend, Y. Tomita, A. Azrilevich, F. Witjes

Institutions: Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, TUM Klinikum, Technical University of Munich, Niigata University, Bristol-Myers Squibb (United States), Radboud University Nijmegen, Radboud University Medical Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2761522084

FWCI: 1.015

Cites:

Cited by: 6

Related to: 10